• 1. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 2. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615

1-Methyl-1H,4H,5H,6H-Pyrrolo[3,4-c]pyrazole Dihydrochloride: A Comprehensive Overview

The compound 1-methyl-1H,4H,5H,6H-pyrrolo[3,4-c]pyrazole dihydrochloride (CAS No. 424819-89-6) is a fascinating molecule that has garnered significant attention in the fields of organic chemistry and pharmacology. This compound belongs to the class of pyrrolopyrazoles, which are heterocyclic structures known for their unique electronic properties and potential biological activities. The dihydrochloride salt form suggests that the compound exists in a protonated state, which may influence its solubility and stability under various conditions.

Recent studies have highlighted the importance of pyrrolopyrazole derivatives in drug discovery. These compounds are being explored for their potential as kinase inhibitors, which are critical in the treatment of various diseases, including cancer. The 1-methyl substitution in this compound adds a methyl group to the pyrrole ring, potentially enhancing its lipophilicity and bioavailability. This modification could play a pivotal role in optimizing the pharmacokinetic properties of the molecule.

The synthesis of 1-methyl-1H,4H,5H,6H-pyrrolo[3,4-c]pyrazole dihydrochloride involves a multi-step process that typically begins with the preparation of pyrrolopyrazole precursors. Researchers have employed various methodologies, including cyclization reactions and Friedel-Crafts alkylation, to construct the core heterocyclic framework. The introduction of the methyl group is often achieved through alkylation or methylation reactions under controlled conditions to ensure regioselectivity.

One of the most promising applications of this compound lies in its potential as a kinase inhibitor. Kinases are enzymes that play a crucial role in cell signaling pathways, and their dysregulation is implicated in numerous diseases. By inhibiting specific kinases, 1-methyl-1H,4H,5H,6H-pyrrolo[3,4-c]pyrazole dihydrochloride could potentially halt the progression of pathological processes such as uncontrolled cell proliferation or inflammation. Preclinical studies have demonstrated moderate inhibitory activity against several kinase targets, making this compound a valuable lead for further optimization.

In addition to its pharmacological applications, this compound has also been studied for its electronic properties. The conjugated system within the pyrrolopyrazole framework allows for efficient electron delocalization, which could be harnessed in materials science applications such as organic electronics or photovoltaic devices. Researchers are currently investigating how modifications to the structure—such as varying substituents or altering ring fusion patterns—can enhance these properties for practical use.

From a structural standpoint, 1-methyl-1H,4H,5H,6H-pyrrolo[3,4-c]pyrazole dihydrochloride exhibits a unique arrangement of nitrogen atoms within its bicyclic system. This arrangement contributes to its aromaticity and stability under physiological conditions. The presence of two adjacent nitrogen atoms in the pyrazole ring creates an electron-deficient environment that can interact with various biomolecules through hydrogen bonding or electrostatic interactions.

Recent advancements in computational chemistry have enabled researchers to perform detailed molecular modeling studies on this compound. These studies have provided insights into its binding modes with target proteins and have guided efforts to improve its potency and selectivity. For instance, molecular dynamics simulations have revealed key residues within kinase active sites that are critical for binding interactions involving this compound.

The dihydrochloride salt form of this compound is particularly advantageous for pharmaceutical applications due to its enhanced solubility in aqueous solutions. This property facilitates drug delivery and ensures consistent bioavailability when administered orally or through other routes. Furthermore, the salt form may stabilize certain conformations of the molecule that are essential for optimal biological activity.

In terms of safety and toxicity profiles, 1-methyl-1H

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)